BioSpace News Archive

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, today announced that it is scheduled to present at the H.C. Wainwright Investor Conference on Monday, September 14, 2020 at 2:00 PM ET. David McNally, President and CEO of Titan will be presenting to a live virtual audience available by webcast at

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study of tidutamab (XmAb ® 18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs) will be presented during the upcoming North American Neuroendoc

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update regarding the Company’s Wand® dental business, as well as the commercial roll-out of its CompuFlo® Epidural System and CathCheck™ technology.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22 nd Annual Global Investment Conference. Event details follow: Date: Tuesday, September 15 th Time: 2:30 p.m. Eastern Time Webcast: https://www.CassavaSciences.com/company-presentations Cassava Sciences’ virtual public

In a long and distinguished career, Bonner has worked tirelessly to bring new innovations to patients that improve outcomes and quality of care

Intensity Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patients have been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy in Phase 2, KEYNO

- Dr. Rosh Dias appointed Chief Medical Officer - - Dan Spiegelman appointed to Board of Directors - SAN FRANCISCO--( BUSINESS WIRE )-- Spruce Biosciences , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the appointments of Dr. Rosh Dias as Chief Medical Officer and Dan Spiegelman to the board of directors. The appoi

- Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC - Brandon Wustman, Ph.D. promoted to Senior Vice President, R&D MENLO PARK, Calif. & DALLAS--( BUSINESS WIRE )-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering precision medicines for life-limiting respiratory diseases, today announced two key executive appointments. Mu

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences: Morgan Stanley Virtual 18 th Annual Global Healthcare Conference on Monday, September 14, 2020 at 9:00 a.m. ET. Bank of America Virtu